CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 22,063	$ 14,113
Selling, general and administrative	7,241	7,664
Gain (Loss) on Disposition of Assets	0	(509)
Total operating expenses	29,304	21,268
Loss from operations	(29,304)	(21,268)
Other income (expense), net:
Interest income	835	3
Interest expense	(1,109)	(913)
Change in fair value of derivative liability	5,439	176
Other income, net	123	60
Total other income (expense), net	5,288	(674)
Loss before provision for income taxes	(24,016)	(21,942)
Provision for income taxes	4	23
Net loss and comprehensive loss	(24,020)	(21,965)
Deemed dividend on Class B Warrant price reset	0	(2,259)
Net loss attributable to common stockholders	$ (24,020)	$ (24,224)
Net loss per share attributable to common stockholders—basic	$ (0.16)	$ (0.72)
Net loss per share attributable to common stockholders—diluted	$ (0.16)	$ (0.72)
Weighted average shares of common stock outstanding—diluted	145,967,000	33,737,000
Weighted average shares of common stock outstanding—basic	145,967,000	33,737,000